William Blair Reaffirms “Outperform” Rating for Allogene Therapeutics (NASDAQ:ALLO)

Allogene Therapeutics (NASDAQ:ALLO)‘s stock had its “outperform” rating reiterated by equities researchers at William Blair in a report issued on Thursday,RTT News reports.

Several other equities research analysts also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Allogene Therapeutics in a report on Friday, November 8th. Canaccord Genuity Group lowered their price target on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Oppenheimer initiated coverage on Allogene Therapeutics in a report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target on the stock. Truist Financial reaffirmed a “buy” rating and set a $14.00 price target (down from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Finally, Citigroup upped their price target on Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.73.

Allogene Therapeutics Stock Down 7.7 %

Shares of ALLO stock opened at $2.27 on Thursday. The stock has a market cap of $475.95 million, a price-to-earnings ratio of -1.46 and a beta of 0.84. The business’s fifty day moving average is $2.75 and its 200 day moving average is $2.66. Allogene Therapeutics has a twelve month low of $2.01 and a twelve month high of $5.78.

Institutional Trading of Allogene Therapeutics

Several institutional investors have recently made changes to their positions in ALLO. Headlands Technologies LLC purchased a new stake in shares of Allogene Therapeutics during the first quarter worth about $78,000. CANADA LIFE ASSURANCE Co boosted its stake in Allogene Therapeutics by 85.1% during the first quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock valued at $79,000 after buying an additional 8,162 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Allogene Therapeutics by 76.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock valued at $18,675,000 after buying an additional 1,806,147 shares during the last quarter. Bourgeon Capital Management LLC boosted its stake in Allogene Therapeutics by 131.6% during the second quarter. Bourgeon Capital Management LLC now owns 132,455 shares of the company’s stock valued at $309,000 after buying an additional 75,255 shares during the last quarter. Finally, Phoenix Wealth Advisors bought a new position in Allogene Therapeutics during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).